- Phare
- Validé par KD/KO
Anticorps Monoclonal anti-PRAME
PRAME Monoclonal Antibody for WB, IF/ICC, Indirect ELISA
Hôte / Isotype
Mouse / IgG2b
Réactivité testée
Humain, rat, souris
Applications
WB, IF/ICC, Indirect ELISA
Conjugaison
Non conjugué
CloneNo.
1E9G9
N° de cat : 68097-1-PBS
Synonymes
Galerie de données de validation
Informations sur le produit
68097-1-PBS cible PRAME dans les applications de WB, IF/ICC, Indirect ELISA et montre une réactivité avec des échantillons Humain, rat, souris
Réactivité | Humain, rat, souris |
Hôte / Isotype | Mouse / IgG2b |
Clonalité | Monoclonal |
Type | Anticorps |
Immunogène | PRAME Protéine recombinante Ag1906 |
Nom complet | preferentially expressed antigen in melanoma |
Masse moléculaire calculée | 509 aa, 58 kDa |
Poids moléculaire observé | 50 kDa |
Numéro d’acquisition GenBank | BC014074 |
Symbole du gène | PRAME |
Identification du gène (NCBI) | 23532 |
Conjugaison | Non conjugué |
Forme | Liquide |
Méthode de purification | Purification par protéine A |
Tampon de stockage | PBS only |
Conditions de stockage | Store at -80°C. 20ul contiennent 0,1% de BSA. |
Informations générales
The PRAME (preferentially expressed antigen of melanoma) gene was previously shown to be overexpressed in ovarian/primary peritoneal serous carcinoma compared with malignant mesothelioma using gene expression arrays. It is considered a melanocyte differentiation antigen which is overexpressed in both solid and hematologic tumors. In normal tissue, a very low level of PRAME expression is found in normal testis, adrenals, ovary and endometrium. A high level of PRAME expression has been reported for several solid tumors, including ovarian cancer, breast cancer, lung cancer and melanomas, medulloblastoma, sarcomas, head and neck cancers, neuroblastoma, renal cancer, and Wilms'tumor. As a nuclear transcriptional repressor protein, PRAME binds to retinoic acid receptor a, thereby inhibiting retinoic acid induced differentiation, growth arrest, and apoptosis.